Real-World Capivasertib Use with Dr. Ruta Rao & Dr. Azadeh Nasrazadani

Managing Capivasertib Toxicity with Drs. Ruta Rao & Azadeh Nasrazadani

PIK3CA-Targeted Therapy After CDK4/6 in HR+ Breast Cancer with Drs. Ruta Rao & Azadeh Nasrazadani

Co-mutations: Sequencing Therapy in ESR1/PIK3CA Patients with Drs. Ruta Rao & Azadeh Nasrazadani

When to Repeat Biomarker Testing in HR+ mBC with Drs. Ruta Rao & Azadeh Nasrazadani

Choosing 2L Therapy After CDK4/6 Inhibitors with Drs. Ruta Rao & Azadeh Nasrazadani

Why First-Line HER2+ Therapy Selection Matters with Drs. Sonya Reid & Shruti Singh

What Comes After First-Line T-DXd? — with Drs. Sonya Reid & Shruti Singh

Continuous T-DXd and the Question of Maintenance—with Drs. Sonya Reid & Shruti Singh

Managing T-DXd Side Effects with Drs. Sonya Reid & Shruti Singh

T-DXd Rechallenge After Early-Stage Treatment with Drs. Sonya Reid & Shruti Singh

Discussing CLEOPATRA and DESTINY-Breast09 with Drs. Sonya Reid & Shruti Singh

Evolving First-Line HER2+ Metastatic Breast Cancer with Drs. Sonya Reid & Shruti Singh

This Moment In Medicine: First-Line HER2+ Metastatic Breast Cancer with Dr. Mothaffar Rimawi

This Moment in Medicine: T-DXd in Early HER2+ BC with Dr. Michelina Cairo

This Moment in Medicine: Rethinking Adjuvant Therapy in ER+ Breast Cancer with Dr. Akshjot Puri

This Moment in Medicine: First-Line ADCs in Metastatic TNBC with Dr. Senthil Damodaran

Do BRCA Patients Benefit from ADCs? | This Moment in Medicine

Oncotype or Prosigna — Which Genomic Test Is More Informative? | This Moment in Medicine

Neoadjuvant or Adjuvant T-DXd? | This Moment in Medicine

Navigating ‘Discordant’ Breast Cancer Genomic Assays | This Moment in Medicine

Gedatolisib Triplet Yields Impressive PFS Curves in HR+ mBC | This Moment in Medicine

How the EMERALD Trial & Elacestrant Changed ER-Positive mBC | This Moment in Medicine

This Moment in Medicine | Breast Cancer Updates That Will Change Clinical Practice

Selecting DESTINY-Breast11 vs. Alternative Approaches with Drs. Abi Siva & Carey Anders

Neoadjuvant T-DXd and pCR in DESTINY-Breast11 with Drs. Abi Siva & Carey Anders

DESTINY-Breast05, DESTINY-Breast11 and T-DXd Integration with Drs. Abi Siva & Carey Anders

Managing Early-Stage T-DXd Toxicities with Drs. Sarah Premji, Reshma Mahtani & Eleftherios Mamounas

First-Line T-DXd in HER2+ mBC with Drs. Sarah Premji, Reshma Mahtani & Eleftherios Mamounas

Adjuvant T-DXd or T-DM1? — with Drs. Sarah Premji, Reshma Mahtani & Eleftherios Mamounas

Managing ILD for Early-Stage T-DXd with Drs. Sarah Premji, Reshma Mahtani & Eleftherios Mamounas

Implementing DESTINY-Breast05 with Drs. Sarah Premji, Reshma Mahtani & Eleftherios Mamounas

DESTINY-Breast11: Early-Stage HER2+ BC with Drs. Sarah Premji, Reshma Mahtani & Eleftherios Mamounas

Camizestrant Safety & Tolerability with Drs. Anne O'Dea & Mabel Mardones

Delaying Time to Chemotherapy in SERENA-6 with Drs. Anne O'Dea & Mabel Mardones

SERENA-6 Quality of Life Benefits with Drs. Anne O'Dea & Mabel Mardones

ESR1 ctDNA Clearance & Early Response in SERENA-6 with Drs. Anne O'Dea & Mabel Mardones

Understanding ESR1 Resistance with Drs. Anne O'Dea & Mabel Mardones

SERENA-6 & ctDNA Monitoring in Practice with Drs. Anne O'Dea & Mabel Mardones

SERENA-6 & ctDNA-Guided Therapy in mBC with Drs. Anne O'Dea & Mabel Mardones

How ASCENT Changed TNBC Care with Drs. Neil Iyengar, Joyce O'Shaughnessy & Ana Garrido-Castro

Why PFS2 Matters in mTNBC with Drs. Neil Iyengar, Joyce O'Shaughnessy & Ana Garrido-Castro

Managing Trop-2 ADC Toxicities with Drs. Neil Iyengar, Joyce O'Shaughnessy & Ana Garrido-Castro

TROPION-Breast02 Results with Drs. Neil Iyengar, Joyce O'Shaughnessy & Ana Garrido-Castro

ASCENT-03 & ASCENT-04 Results with Drs. Neil Iyengar, Joyce O'Shaughnessy & Ana Garrido-Castro

Does Crossover Affect OS? with Drs. Neil Iyengar, Joyce O'Shaughnessy & Ana Garrido-Castro

Evolving ADCs in 1L mTNBC with Drs. Neil Iyengar, Joyce O'Shaughnessy & Ana Garrido-Castro

Interpreting Overall Survival & PFS in mTNBC ADC Trials with Drs. Sangeetha Reddy & Ahmed Elkhanany

EMERALD-3 Roundtable: Is Multidisciplinary Care the Future of Intermediate-Stage HCC?

EMERALD-3 Roundtable: Low Hepatitis Rates with Durvalumab, Tremelimumab & TACE in HCC

EMERALD-3 Roundtable: Can We Apply TACE + Immunotherapy Data to TARE?

EMERALD-3 Roundtable: Why PFS Matters More Than Ever in Hepatocellular Carcinoma

EMERALD-3 Roundtable: Are HCC Trials Reflecting Real-World Practice?

EMERALD-3 Roundtable: The Role of CTLA-4 in Long-Term HCC Survival

PTEN Loss & AKT Therapy Resistance in HR+/HER2-mBC with Drs. Ursa Brown Glaberman & Karthik Giridhar

Strategies for Successful Capivasertib Management with Drs. Ursa Brown-Glaberman & Karthik Giridhar

Proactive Toxicity Management for Capivasertib with Drs. Ursa Brown-Glaberman & Karthik Giridhar

PI3K/AKT-Directed Second-Line Therapy in HR+ mBC with Drs. Ursa Brown-Glaberman & Karthik Giridhar

Biomarker Testing in HR+ mBC with Drs. Ursa Brown-Glaberman & Karthik Giridhar

Maximizing Endocrine Therapy in HR+ mBC with Drs. Ursa Brown-Glaberman & Karthik Giridhar